Zacks Investment Research upgraded shares of Coloplast A/S (OTCMKTS:CLPBY) from a sell rating to a hold rating in a research note released on Wednesday, March 7th.
According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “
Shares of Coloplast A/S (CLPBY) traded down $0.01 during midday trading on Wednesday, reaching $8.45. 36,251 shares of the company were exchanged, compared to its average volume of 148,741. Coloplast A/S has a fifty-two week low of $7.15 and a fifty-two week high of $9.01.
Coloplast A/S (OTCMKTS:CLPBY) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.07 earnings per share for the quarter. The company had revenue of $625.80 million during the quarter. analysts expect that Coloplast A/S will post 0.31 EPS for the current fiscal year.
Coloplast A/S Company Profile
Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Urology Care, and Wound & Skin Care. It provides ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.